Clinical Trial: FDA Approved Drugs in Other Cancers (Dabrafenib/Trametinib) Now Used In Early Myeloma Clinical Trial for Relapsed/Refractory Patients

The drugs Trametinib or Dabrafenib have been FDA approved in other cancers. Some cancers, including myeloma, have changes (mutations) in a gene called BRAF or other genes, called KRAS or NRAS. These three genes tell the body to make a protein called BRAF, KRAS, or NRAS, respectively, which are all involved in sending signals in cells that can lead to cell growth. Certain mutations in these three genes cause a change in these proteins that can increase the growth and spread of cancer cells. Dabrafenib and trametinib work to prevent these altered proteins from working and sending signals in cancer cells, and thereby may block the growth and spread of cancer cells in people with cancers with BRAF, KRAS, or NRAS gene mutations.

Dabrafenib and trametinib have been used in the treatment for other cancers in other research studies, and information from those research studies suggest that these agents may help to kill multiple myeloma cells. Dabrafenib and trametinib, which are investigated in this research study may or may not kill myeloma cells effectively. We would like to see if these drugs given alone or in combination safely and effectively kill these cancer cells.

Dabrafenib is a Kinase Inhibitor while Trametinib  is a MEK Inhibitor. This trial is open and accepting patients at Massachusetts General Hospital in Boston, MA. 

To learn more and find the closest trial site, click here: 

Dabrafenib/Trametinib Clinical Trial

Find eligible clinical trials for your myeloma, click here: 

Find all Myeloma Clinical Trials